{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-046908","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.035651+00:00","generated_at":"2026-05-29T21:50:55.677249+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biotricity Q2 FY2025 revenue up 13% YoY to $3.3M; net loss down 57% to $1.65M","bullets":["Revenue $3.3M (+13% YoY); gross margin improved to 75.3% from 69.1%.","Net loss decreased 57% to $1.65M ($0.073/share) from $3.88M in Q2 FY24.","Recurring tech fees $3.06M (+12.2%), 94% of total revenue; flat fee portion up 34%.","Achieved positive cash flow on current operating basis in September; expects continued improvement.","SG&A cut 35.5% to $2.25M; total operating expenses down 34% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-046908","json":"https://secwatch.observer/filing/0001493152-24-046908.json","markdown":"https://secwatch.observer/filing/0001493152-24-046908.md","text":"https://secwatch.observer/filing/0001493152-24-046908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224046908/0001493152-24-046908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315224046908/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T21:50:55.677249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}